Abbott Laboratories
ABT124.845USD
+0.035+0.03%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
217.09BMarket Cap
15.54P/E TTM
More Details of Abbott Laboratories Company
Abbott Laboratories is an American multinational health care and medical devices corporation headquartered in Abbott Park, Illinois. Founded in 1888 by Chicago physician Wallace Calvin Abbott, the company initially focused on formulating known drugs. Today, it offers medical devices, diagnostics, branded generic medications, and nutritional products. In 2013, Abbott separated its research-based pharmaceuticals division into AbbVie.
Abbott's product lineup includes Pedialyte, Similac, BinaxNOW, Ensure, Glucerna, ZonePerfect, FreeStyle Libre, i-STAT, and MitraClip.
Abbott Laboratories Info
Ticker SymbolABT
Company nameAbbott Laboratories
IPO dateApr 06, 2073
CEOFord (Robert B)
Number of employees114000
Security typeOrdinary Share
Fiscal year-endApr 06
Address100 Abbott Park Road
CityABBOTT PARK
Stock exchangeNASDAQ OMX NASDAQ Basic NYSE
CountryUnited States of America
Postal code60064-3500
Phone12246676100
Websitehttps://www.abbott.com
Ticker SymbolABT
IPO dateApr 06, 2073
CEOFord (Robert B)
Company Executives of Abbott Laboratories
Name
Name/Position
Position
Shareholding
Change
Mr. Daniel J. Starks
Mr. Daniel J. Starks
Independent Director
Independent Director
6.73M
+0.02%
Mr. Hubert L. Allen
Mr. Hubert L. Allen
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
191.90K
+3.84%
Mr. Daniel Gesua Sive Salvadori
Mr. Daniel Gesua Sive Salvadori
Executive Vice President, Group President - Established Pharmaceuticals and Nutritional Products
Executive Vice President, Group President - Established Pharmaceuticals and Nutritional Products
133.77K
+6.42%
Ms. Mary K. Moreland
Ms. Mary K. Moreland
Executive Vice President - Human Resources
Executive Vice President - Human Resources
95.58K
-0.82%
Ms. Lisa D. Earnhardt
Ms. Lisa D. Earnhardt
Executive Vice President, Group President - Medical Devices
Executive Vice President, Group President - Medical Devices
71.93K
--
Mr. Louis H. (Lou) Morrone
Mr. Louis H. (Lou) Morrone
Executive Vice President - Core Diagnostics
Executive Vice President - Core Diagnostics
66.61K
-0.40%
Mr. Philip P. Boudreau
Mr. Philip P. Boudreau
Chief Financial Officer, Executive Vice President - Finance
Chief Financial Officer, Executive Vice President - Finance
50.97K
-0.75%
Dr. Robert J. Alpern, M.D.
Dr. Robert J. Alpern, M.D.
Independent Director
Independent Director
40.80K
+4.17%
Ms. Nancy Mckinstry
Ms. Nancy Mckinstry
Lead Independent Director
Lead Independent Director
38.72K
+4.41%
Ms. Sally E. Blount, Ph.D.
Ms. Sally E. Blount, Ph.D.
Independent Director
Independent Director
34.06K
-2.76%
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Daniel J. Starks
Mr. Daniel J. Starks
Independent Director
Independent Director
6.73M
+0.02%
Mr. Hubert L. Allen
Mr. Hubert L. Allen
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
191.90K
+3.84%
Mr. Daniel Gesua Sive Salvadori
Mr. Daniel Gesua Sive Salvadori
Executive Vice President, Group President - Established Pharmaceuticals and Nutritional Products
Executive Vice President, Group President - Established Pharmaceuticals and Nutritional Products
133.77K
+6.42%
Ms. Mary K. Moreland
Ms. Mary K. Moreland
Executive Vice President - Human Resources
Executive Vice President - Human Resources
95.58K
-0.82%
Ms. Lisa D. Earnhardt
Ms. Lisa D. Earnhardt
Executive Vice President, Group President - Medical Devices
Executive Vice President, Group President - Medical Devices
71.93K
--
Mr. Louis H. (Lou) Morrone
Mr. Louis H. (Lou) Morrone
Executive Vice President - Core Diagnostics
Executive Vice President - Core Diagnostics
66.61K
-0.40%
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Diabetes Care
1.98B
17.78%
Core Laboratory
1.36B
12.19%
Adult Nutritionals
1.16B
10.39%
Key Emerging Markets
1.06B
9.50%
Pediatric Nutritionals
1.05B
9.46%
Other
4.53B
40.67%
By RegionUSD
Name
Revenue
Proportion
All other Countries
6.87B
61.62%
United States
4.28B
38.38%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Diabetes Care
1.98B
17.78%
Core Laboratory
1.36B
12.19%
Adult Nutritionals
1.16B
10.39%
Key Emerging Markets
1.06B
9.50%
Pediatric Nutritionals
1.05B
9.46%
Other
4.53B
40.67%
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
10.06%
BlackRock Institutional Trust Company, N.A.
5.13%
State Street Investment Management (US)
4.50%
Capital International Investors
3.54%
Capital Research Global Investors
2.23%
Other
74.54%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
10.06%
BlackRock Institutional Trust Company, N.A.
5.13%
State Street Investment Management (US)
4.50%
Capital International Investors
3.54%
Capital Research Global Investors
2.23%
Other
74.54%
Shareholder Types
Shareholders
Proportion
Investment Advisor
47.15%
Investment Advisor/Hedge Fund
23.10%
Research Firm
3.49%
Pension Fund
2.34%
Bank and Trust
2.20%
Sovereign Wealth Fund
1.37%
Insurance Company
1.02%
Hedge Fund
0.49%
Individual Investor
0.48%
Other
18.36%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
4606
1.42B
81.82%
+3.92M
2025Q3
4681
1.42B
81.87%
+8.53M
2025Q2
4668
1.41B
81.51%
+6.23M
2025Q1
4636
1.40B
80.10%
+7.18M
2024Q4
4554
1.38B
78.81%
+33.68M
2024Q3
4367
1.35B
78.83%
-5.95M
2024Q2
4376
1.35B
78.36%
+5.03M
2024Q1
4375
1.35B
77.56%
-1.86M
2023Q4
4400
1.34B
77.62%
+7.10M
2023Q3
4258
1.33B
78.26%
-4.16M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
172.03M
9.88%
+2.96M
+1.75%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
88.52M
5.09%
+696.11K
+0.79%
Jun 30, 2025
State Street Investment Management (US)
78.35M
4.5%
+689.52K
+0.89%
Jun 30, 2025
Capital International Investors
60.14M
3.46%
-6.69M
-10.01%
Jun 30, 2025
Capital Research Global Investors
41.77M
2.4%
-8.97M
-17.68%
Jun 30, 2025
Geode Capital Management, L.L.C.
38.29M
2.2%
+1.39M
+3.77%
Jun 30, 2025
Wellington Management Company, LLP
25.05M
1.44%
-4.71M
-15.83%
Jun 30, 2025
Norges Bank Investment Management (NBIM)
22.25M
1.28%
+1.27M
+6.03%
Jun 30, 2025
JP Morgan Asset Management
26.38M
1.52%
-2.42M
-8.39%
Jun 30, 2025
View more
Related ETFs
Updated: Wed, Nov 5
Updated: Wed, Nov 5
Name
Proportion
iShares U.S. Medical Devices ETF
19.31%
Goldman Sachs Future Health Care Equity ETF
6.26%
SMI 3Fourteen Full-Cycle Trend ETF
5.01%
Invesco Pharmaceuticals ETF
4.99%
Health Care Select Sector SPDR Fund
4.62%
Proshares Ultra Health Care
4.61%
Tema Heart & Health ETF
4.5%
iShares U.S. Healthcare ETF
4.42%
AdvisorShares Focused Equity ETF
4.37%
Polen Capital Global Growth ETF
4.27%
View more
iShares U.S. Medical Devices ETF
Proportion19.31%
Goldman Sachs Future Health Care Equity ETF
Proportion6.26%
SMI 3Fourteen Full-Cycle Trend ETF
Proportion5.01%
Invesco Pharmaceuticals ETF
Proportion4.99%
Health Care Select Sector SPDR Fund
Proportion4.62%
Proshares Ultra Health Care
Proportion4.61%
Tema Heart & Health ETF
Proportion4.5%
iShares U.S. Healthcare ETF
Proportion4.42%
AdvisorShares Focused Equity ETF
Proportion4.37%
Polen Capital Global Growth ETF
Proportion4.27%
Dividend
A total of
16.46B
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
Dec 12, 2025
ABT.NB Final Cash Dividend of gross USD 0.63 paid on Feb 13, 2026 going ex on Jan 15, 2026 with reinvestment option
Jan 15, 2026
Feb 13, 2026
Jan 15, 2026
Sep 19, 2025
ABT.NB Interim Cash Dividend of gross USD 0.59 paid on Nov 17, 2025 going ex on Oct 15, 2025 with reinvestment option
Oct 15, 2025
Nov 17, 2025
Oct 15, 2025
Jun 13, 2025
ABT.NB Interim Cash Dividend of gross USD 0.59 paid on Aug 15, 2025 going ex on Jul 15, 2025 with reinvestment option
Jul 15, 2025
Aug 15, 2025
Jul 15, 2025
Feb 21, 2025
ABT.NB Interim Cash Dividend of gross USD 0.59 paid on May 15, 2025 going ex on Apr 15, 2025 with reinvestment option
Apr 15, 2025
May 15, 2025
Apr 15, 2025
Dec 13, 2024
ABT.NB Final Cash Dividend of gross USD 0.59 paid on Feb 14, 2025 going ex on Jan 15, 2025 with reinvestment option
Jan 15, 2025
Feb 14, 2025
Jan 15, 2025
Sep 19, 2024
ABT.NB Final Cash Dividend of gross USD 0.55 paid on Nov 15, 2024 going ex on Oct 15, 2024
Oct 15, 2024
Nov 15, 2024
Oct 15, 2024
Jun 15, 2024
ABT.NB Interim Cash Dividend of gross USD 0.55 paid on Aug 15, 2024 going ex on Jul 15, 2024 with reinvestment option
Jul 15, 2024
Aug 15, 2024
Jul 15, 2024
Feb 16, 2024
ABT.NB Interim Cash Dividend of gross USD 0.55 paid on May 15, 2024 going ex on Apr 12, 2024
Apr 15, 2024
May 15, 2024
Apr 12, 2024
Dec 15, 2023
ABT.NB Interim Cash Dividend of gross USD 0.55 paid on Feb 15, 2024 going ex on Jan 11, 2024 with reinvestment option
Jan 12, 2024
Feb 15, 2024
Jan 11, 2024
Sep 21, 2023
ABT.NB Interim Cash Dividend of gross USD 0.51 paid on Nov 15, 2023 going ex on Oct 12, 2023 with reinvestment option
Oct 13, 2023
Nov 15, 2023
Oct 12, 2023
View more
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Abbott Laboratories?
The top five shareholders of Abbott Laboratories are:
The Vanguard Group, Inc. holds 172.03M shares, accounting for 9.88% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 88.52M shares, accounting for 5.09% of the total shares.
State Street Investment Management (US) holds 78.35M shares, accounting for 4.50% of the total shares.
Capital International Investors holds 60.14M shares, accounting for 3.46% of the total shares.
Capital Research Global Investors holds 41.77M shares, accounting for 2.40% of the total shares.
The Vanguard Group, Inc. holds 172.03M shares, accounting for 9.88% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 88.52M shares, accounting for 5.09% of the total shares.
State Street Investment Management (US) holds 78.35M shares, accounting for 4.50% of the total shares.
Capital International Investors holds 60.14M shares, accounting for 3.46% of the total shares.
Capital Research Global Investors holds 41.77M shares, accounting for 2.40% of the total shares.
What are the top three shareholder types of Abbott Laboratories?
The top three shareholder types of Abbott Laboratories are:
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
State Street Investment Management (US)
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
State Street Investment Management (US)
How many institutions hold shares of Abbott Laboratories (ABT)?
As of 2025Q4, 4606 institutions hold shares of Abbott Laboratories, with a combined market value of approximately 1.42B, accounting for 81.82% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -0.05%.
What is the biggest source of revenue for Abbott Laboratories?
In FY2025Q2, the Diabetes Care business generated the highest revenue for Abbott Laboratories, amounting to 1.98B and accounting for 17.78% of total revenue.
